Sana Biotechnology (SANA) EBT (2020 - 2026)

Sana Biotechnology has reported EBT for 7 years, with the latest figure at -$162.4 million in Q1 2026.

• Quarterly EBT rose 25.17% year-over-year to -$162.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$534.9 million (up 16.4% YoY) and the FY2025 annual result came in at -$369.6 million, down 5.54% from the prior year.
• EBT retreated to -$162.4 million in Q1 2026 per SANA's latest filing, from -$61.2 million in the prior quarter.
• Over five years, EBT peaked at -$52.4 million in Q4 2024 and troughed at -$493.1 million in Q4 2023.
• A 5-year average of -$193.9 million and a median of -$196.7 million in 2024 frame the typical range for EBT.
• The sharpest annual moves came in 2022 and 2024: EBT sank 773.18% in 2022, then jumped 89.38% in 2024.
• Over 5 years, EBT stood at -$83.4 million in 2022, then plunged by 491.21% to -$493.1 million in 2023, then surged by 89.38% to -$52.4 million in 2024, then slipped by 16.82% to -$61.2 million in 2025, then sank by 165.42% to -$162.4 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$162.4 million, -$61.2 million, and -$86.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.